118 related articles for article (PubMed ID: 2877693)
1. [Seasonal changes in the behavioral effects of neuroleptics on white rats].
Otter MIa; Kalda EI; Erik IuP
Biull Eksp Biol Med; 1986 Nov; 102(11):577-9. PubMed ID: 2877693
[TBL] [Abstract][Full Text] [Related]
2. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
[TBL] [Abstract][Full Text] [Related]
3. [Increased tolerance of the dopamine- and serotoninergic systems during chronic administration of haloperidol and levomepromazine].
Allikmets LKh; Zharkovskiĭ AM; Otter MIa; Khinrikus TKh
Zh Vyssh Nerv Deiat Im I P Pavlova; 1979; 29(5):1067-70. PubMed ID: 573939
[TBL] [Abstract][Full Text] [Related]
4. The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan.
Maj J; Baran L; Bigajska K; Rogóz Z; Skuza G
Pol J Pharmacol Pharm; 1978; 30(4):431-40. PubMed ID: 33367
[TBL] [Abstract][Full Text] [Related]
5. [Homovanilic acid accumulation in the brain of rats as a possible cause of the inhibitory action of psychotropic substances on behavior and motor activity].
Zharkovskiĭ AM; Allikmets LKh
Farmakol Toksikol; 1979; 42(5):467-70. PubMed ID: 39774
[TBL] [Abstract][Full Text] [Related]
6. [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol].
Kikumoto O; Okamoto Y; Hayakawa H; Yokota N; Kawai K; Motohashi N; Yamawaki S
Yakubutsu Seishin Kodo; 1993 Feb; 13(1):39-42. PubMed ID: 7686319
[TBL] [Abstract][Full Text] [Related]
7. In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration.
Kulkarni SK; Bishnoi M; Chopra K
Indian J Exp Biol; 2009 Feb; 47(2):91-7. PubMed ID: 19374163
[TBL] [Abstract][Full Text] [Related]
8. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
Christensen AV; Arnt J; Hyttel J; Svendsen O
Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
[TBL] [Abstract][Full Text] [Related]
9. Effect of serotonergic agents on neuroleptic induced catalepsy in rats.
Rao SG; Hrishikeshavan HJ; Guruswami MN
Funct Neurol; 1990; 5(4):353-60. PubMed ID: 1982664
[TBL] [Abstract][Full Text] [Related]
10. [Afobazole decreases motor side effects induced by haloperidol].
Seredenin SB; Garibova TA; Kuznetsova AL; Voronin MV; Iarkova MA; Voronina TA
Eksp Klin Farmakol; 2009; 72(1):15-8. PubMed ID: 19334504
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
12. A comparison between some biochemical and behavioural effects produced by neuroleptics.
Fregnan GB; Porta R
Arzneimittelforschung; 1981; 31(1):70-4. PubMed ID: 6111328
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug.
Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M
Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413
[TBL] [Abstract][Full Text] [Related]
14. Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment.
Biazzi A; Fregnan GB
Adv Biochem Psychopharmacol; 1980; 24():351-7. PubMed ID: 6105785
[No Abstract] [Full Text] [Related]
15. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
17. A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol.
Umathe SN; Wanjari MM; Manna SS; Jain NS
Neuropeptides; 2009 Jun; 43(3):251-7. PubMed ID: 19403167
[TBL] [Abstract][Full Text] [Related]
18. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
19. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
[TBL] [Abstract][Full Text] [Related]
20. Behavioral pharmacologic studies in the monkey with DD-3480.
Shibuya T; Nishimori T; Matsuda H; Chen PC
Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):251-4. PubMed ID: 6125481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
